Skip to main content
SURMODICS INC logo

SURMODICS INC — Investor Relations & Filings

Ticker · SRDX ISIN · US8688731004 LEI · 549300H76KXCAAGUS878 US Manufacturing
Open in API
Filings indexed 1,062 across all filing types
Latest filing 2014-11-06 Capital/Financing Update
Country US United States of America
Listing US SRDX

About SURMODICS INC

https://www.surmodics.com/

Surmodics, Inc. provides performance-enhancing technologies for the healthcare industry, focusing on medical devices and in vitro diagnostics. The company is a leading provider of surface modification technologies, offering customized hydrophilic, hemocompatible, and drug-delivery coatings for intravascular medical devices. In addition to its coatings business, Surmodics develops and commercializes a portfolio of vascular intervention medical devices for the treatment of peripheral arterial and venous disease, including thrombectomy and radial access platforms. The company also offers end-to-end contract development and manufacturing services. Its In Vitro Diagnostics (IVD) division supplies critical chemical components for immunoassays and microarrays, aiming to enhance the sensitivity and reproducibility of diagnostic tests.

Recent filings

Filing Released Lang Actions
8-K Filing
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated November 5, 2014. It includes an announcement of a First Amendment to a Credit Agreement (a financing activity) and a press release about quarterly results. It also announces a share repurchase program authorized by the Board. The document is relatively short (4214 characters) and primarily serves as an announcement of these events rather than containing detailed financial statements or comprehensive financial analysis. The key content relates to financing amendments and share repurchase authorization. Therefore, the most appropriate classification is Capital/Financing Update (CAP), as it covers updates on financing activities and capital structure changes. It is not a full financial report, earnings release, or regulatory filing of another type.
2014-11-06 English
SURMODICS, INC. 8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filing with the SEC, dated October 3, 2014, reporting the departure of a director or certain officer (Mark A. Lehman, controller and principal accounting officer). The key content is about the mutual agreement to end employment and transition arrangements. This matches the description of Board/Management Information filings, which announce changes in the company's board of directors or senior management. The document is short (2394 characters) and focused solely on management change, not financial results or other report types.
2014-10-08 English
FORM 4 SUBMISSION
Director's Dealing
2014-10-02 English
FORM 4 SUBMISSION
Director's Dealing
2014-10-02 English
4 Filing
Director's Dealing
2014-10-02 English
4 Filing
Director's Dealing
2014-09-04 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.